Sanara MedTech Inc. — Major Shareholding Notification 2019

Nov 18, 2019

SC 13D/A 1 smti_sc13da.htm SC-13D/A Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2019 Issuer Direct Corporation Blueprint

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

| Sanara
MedTech, Inc. |
| --- |
| (Name
of Issuer) |

| Common
Stock, $.001 par value |
| --- |
| (Title
of Class of Securities) |

79957L100
(CUSIP
Number)

| Howell,
S. Oden, Jr., Sanara MedTech, Inc. 1200 Summit Ave, Suite 414 Fort
Worth, TX 76102 Phone: 817-529-2300 |
| --- |
| (Name,
Address and Telephone Number of Person Authorized to Receive
Notices and Communications) |
| October
15, 2019 |
| (Date
of Event which Requires Filing of this Statement) |

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

page break

SCHEDULE 13D

CUSIP No. 79957L100

| 1 | NAMES
OF REPORTING PERSONSI.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY) | |
| --- | --- | --- |
| | Howell
S. Oden Jr. | |
| 2 | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP | |
| | (a) [
] (b) [
√] | |
| 3 | SEC USE
ONLY | |
| 4 | SOURCE
OF FUNDS (See Instructions) | |
| | 00 | |
| 5 | CHECK
IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(D) OR 2(E) | |
| | [
] | |
| 6 | CITIZENSHIP
OR PLACE OF ORGANIZATION | |
| | United
States | |
| NUMBER
OFSHARESBENEFICIALLYOWNED BYEACHREPORTINGPERSONWITH | 7 | SOLE
VOTING POWER |
| | | 481,165 |
| | 8 | SHARED
VOTING POWER |
| | 9 | SOLE
DISPOSITIVE POWER |
| | | 481,165 |
| | 10 | SHARED
DISPOSITIVE POWER |
| 11 | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| | 481,165 | |
| 12 | CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions) | |
| | [ ] | |
| 13 | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
| | 13.47% | |
| 14 | TYPE OF
REPORTING PERSON (See Instructions) | |
| | IN | |

• The percentage is based upon 3,571,001 outstanding shares of Common Stock, as reported on the Issuer’s Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2019.

Explanatory Note

This Amendment No. 2 to the Statement on Schedule 13D (this “Amendment No. 2”) is being filed with respect to the common stock, par value $0.001 per share (the “Common Stock”), of Sanara MedTech Inc., a Texas corporation (the “Company”), to amend and supplement the Statement on Schedule 13D filed by Solomon Ogden Howell, Jr. (the “Reporting Person”) on February 26, 2019 (the “Original Schedule 13D”), as amended by Amendment No. 1 to the Original Schedule 13D filed by the Original Reporting Persons on July 10, 2019. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D.

page break

The Reporting Persons are filing this Amendment No. 2 to reflect their respective ownership of Common Stock following the Issuance (as defined below). Except as set forth herein, all Items are unchanged.

Item 3.

Source and Amount of Funds or Other Considerations

Item 3 is supplemented as follows:

On October 15, 2019, the Solomon Oden Howell Revocable Trust entered into a Subscription Agreement pursuant to which the Issuer issued 60,241 shares of its Common Stock for a total subscription price of $500,000 (the “Issuance”).

Item 5.

Interest in Securities of the Issuer

Item 5 is amended as follows:

(a)

The information set forth on rows 11 and 13 of the cover pages of this Schedule 13D is incorporated by reference. The percentage is based upon 3,571,001 outstanding shares of Common Stock, as reported on the Issuer’s Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2019 .

(b)

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

Item 7.

Material to Be Filed as Exhibits

Exhibit 10.1 - Subscription Agreement between Sanara MedTech Inc. and Solomon Oden Howell Revocable Trust.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated
November
15, 2019
Signature
/s/
Solomon Oden Howell, Jr.

page break

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

page break